Hit HIV-1 hard, but only when necessary

Lancet

Volumn 355, Issue 9221, 2000, Pages 2147-2152

  Harrington, Mark ^a   Carpenter, Charles C J ^b  

^a Treatment Action Group   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BONE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIPODYSTROPHY; LYMPHOCYTE COUNT; MORTALITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL; VIRUS LOAD;

EID: 0034679324     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02388-6     Document Type: Review

References (37)

1. Delfraissy J-F. Prise en charge thérapeutique des personnes infectées par le VIH: recommendations du groupe d'experts - Rapport 1999. Paris: Médecine-Sciences Flammarion, 1999 (available online at www.sante.gouv.fr/htm/dossiers/sidahop/index_delfra.htm).
2. Pozniak A, Gazzard BG, Churchill D, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. London: BHIVA, December, 1999 (available online at www.aidsmap.com/bhiva/bhivagd1299.htm).
3. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA Panel. JAMA 2000; 283: 381-91.
4. Department of Health and Human Services/Henry J Kaiser Family Foundation Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Rockville, MD: HIV/AIDS Treatment Information Service, January, 2000 (available online at www.hivatis.org/guidelines/adult/pdf/A&ajani.pdf).
5. National Program on STD/AIDS, Secretariat for Health Policy. Recommendations on antiretroviral therapy for HIV-infected adults and adolescents. Brasilia: Ministry of Health, 1999.
6. Cohen OJ, Fauci AS. Benchmarks for antiretroviral therapy. J Clin Invest 2000; 105: 709-10.
7. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278: 1447-50.
8. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998; 351: 543-49.
9. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33.
10. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in human immunodeficiency virus-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081-90.
11. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced HIV infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
12. Junghans C, Low N, Chan P, et al. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS 1999; 13: 2547-54.
13. Meibohm A, Alexander J, Robertson M, et al. Early versus late initiation of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC) in HIV-1-infected adults. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February, 2000 (abstr 521).
14. Rizzardi GP, De Boer RJ, Hoover S, et al. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. J Clin Invest 2000; 105: 777-82.
15. Gallant JE. Strategies for long-term success in the treatment of HIV infection. JAMA 2000; 283: 1329-34.
16. Carr A, Samaras K, Burton S. A syndrome of peripheral lipodystrophy (LD), hyperlipidemia and insulin resistance due to HIV protease inhibitors (PIs). Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February, 1998 (abstr 410).
17. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13: 2493-505.
18. Lucas GM, Chaisson RE, Moore RE. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern 1999; 131: 81-87.
19. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States. JAMA 1999; 281: 2305-15.
20. Deeks SG, Barbour JD, Martin JN, et al. Delayed immunologic deterioration among patients who virologically fail protease inhibitor-based therapy. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February, 2000 (abstr 236).
21. Paterson D, Swindells S, Mohr J, et al. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMS caps. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, February, 1999 (abstr 92).
22. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir of human immunodeficiency virus-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-300.
23. Chun TW, Davey R, Ostrowski M, et al. Relationship between preexisting latent viral reservoirs and the reemergence of plasma viremia after discontinuation of HAART. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February, 2000 (abstr 239).
24. Ho DD. Dynamics of HIV-1 replication in vivo. J Clin Invest 1997; 99: 2565-67.
25. Rouzine IM, Coffin JM. Linkage disequilibrium test implies a large effective population number for HIV in vivo. Proc Natl Acad Sci USA 1999; 96: 10758-63.
26. Decks SG, Wrin T, Barbour JD, et al. Decreased HIV-1 fitness after long-term virologic failure of pro tease inhibitor-based therapy: relationship to immune response. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February, 2000 (abstr 156).
27. Cooper DA, Emery S. Therapeutic strategies for HIV infection: time to think hard. N Engl J Med 1998; 339: 1319-21.
28. Autran B, Carcelain G, Li TS, et al. Positive effects of combined ART on CD4+ T cell homeostasis and function in advanced human immunodeficiency virus disease. Science 1997; 277: 112-6.
29. Zhang ZQ, Notermans DW, Sedgewick G, et al. Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci USA 1998; 95: 1154-59.
30. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396: 690-95.
31. Komanduri KV, Viswanathan MN, Wider ED, et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998; 4: 953-56.
32. Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA 1999; 282: 1633-37.
33. Weverling GJ, Mocroft A, Ledergerber B. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet 1999; 353: 1293-98.
34. Currier JS, Williams PL, Koletar S, et al. A randomized, placebo-controlled trial of azithromycin prophylaxis for the prevention of Mycobacterium avium complex (MAC) in subjects with increases in CD4 cells on antiretroviral therapy. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, February, 1999 (abstr LB-23).
35. CDC. 1999 USPHS guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. US Public Health Service and Infectious Disease Society of America. MMWR Morb Mortal Wkly Rep 1999; 48 (RR-10): 1-82.
36. Phair J, Muñoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990; 322: 161-65.
37. Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999; 5: 518-25.